Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
BF Haynes, K Wiehe, P Borrow, KO Saunders… - Nature Reviews …, 2023 - nature.com
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
Antibodies to combat viral infections: development strategies and progress
G Pantaleo, B Correia, C Fenwick, VS Joo… - Nature Reviews Drug …, 2022 - nature.com
Monoclonal antibodies (mAbs) are appealing as potential therapeutics and prophylactics for
viral infections owing to characteristics such as their high specificity and their ability to …
viral infections owing to characteristics such as their high specificity and their ability to …
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
L Stamatatos, J Czartoski, YH Wan, LJ Homad, V Rubin… - Science, 2021 - science.org
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …
raised concerns about resistance to neutralizing antibodies elicited by previous infection or …
[HTML][HTML] Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding
The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …
attachment to ACE2 receptor and is a major determinant of host range and a dominant target …
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
Countermeasures to prevent and treat coronavirus disease 2019 (COVID-19) are a global
health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 …
health priority. We enrolled a cohort of severe acute respiratory syndrome coronavirus 2 …
Development of therapeutic antibodies for the treatment of diseases
It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …
the United States Food and Drug Administration (US FDA) in 1986, and during this time …
[HTML][HTML] Human neutralizing antibodies elicited by SARS-CoV-2 infection
Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global health emergency that …
respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global health emergency that …
[HTML][HTML] Antibodies from primary humoral responses modulate the recruitment of naive B cells during secondary responses
Vaccines generate high-affinity antibodies by recruiting antigen-specific B cells to germinal
centers (GCs), but the mechanisms governing the recruitment to GCs on secondary …
centers (GCs), but the mechanisms governing the recruitment to GCs on secondary …
Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection
Pre-existing immunity to seasonal endemic coronaviruses could have profound
consequences for antibody responses to SARS-CoV-2, induced from natural infection or …
consequences for antibody responses to SARS-CoV-2, induced from natural infection or …
Emerging concepts and technologies in vaccine development
Despite the success of vaccination to greatly mitigate or eliminate threat of diseases caused
by pathogens, there are still known diseases and emerging pathogens for which the …
by pathogens, there are still known diseases and emerging pathogens for which the …